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Slltninlary 
K46J B lymphomas express a T cell costimulatory activity that is not inhibited by CTLA-4Ig, 
anti-B7-1, anti-B7-2, anti-intercellular adhesion molecule 1 or antibodies to heat stable antigen. 
In this paper we report that this costimulatory activity is mediated at least in part by 4-1BB 
ligand, a member of the tumor necrosis factor (TNF) gene family that binds to 4-1BB,  a T 
cell activation antigen with homology to the TNF/nerve growth factor receptor family. A fusion 
protein between 4-1BB  and alkaline phosphatase (4-1BB-AP) blocks T  cell activation by K46J 
lymphomas in both an antigen-specific system and with polyclonally (anti-CD3)  activated T 
cells. 4-1BB-AP also blocks antigen presentation by normal spleen cells. When the antigen-presenting 
cells express B7 molecules as well as 4-1BB ligand, we find that B7 molecules and 4-1BB-AP 
both contribute to T  cell activation. These data suggest that 4-1BB ligand plays an important 
role in costimulation of IL-2 production and proliferation by T  cells. The B lymphoma M12 
expresses low levels of 4-1BB-L but can be induced to express higher levels by treatment of the 
B ceils with cAMP, which also induces B7-1  and B7-2 in these cells. Thus cAMP appears  to 
coordinately induce several costimulatory molecules on B cells. 
T  lymphocyte activation requires two signals.  Signal I is 
provided when an antigen/MHC complex binds to the 
TCR and signal 2 is provided by TCR-independent interac- 
tions (1). The binding of costimulatory molecules B7-1  or 
B7-2 to CD28 on the T  cell is now widely recognized as 
providing an important costimulatory signal for inducing high 
level IL-2 production and proliferation ofT cells (2, 3). How- 
ever, other molecules have been reported to have costimulatory 
roles in T  cell activation. For example, the heat stable  an- 
tigen has been reported to have costimulatory activity for T 
cell activation that synergizes with B7 (4-6). Intercellular and 
vascular cell adhesion molecules 1 (ICAM-1 and VCAM-1) 1, 
the ligands, respectively, for LFA-1  and very late antigen 4 
have also been shown to costimulate with anti-TCR in the 
costimulation of resting T  cells (7).  More recently, 4-1BB- 
ligand(L)-4-1BB interaction has been suggested to play a role 
in the costimulation of lymphocyte growth (8,  9). 
4-1BB is a 55-kD protein expressed on activated CD4 and 
1 Abbreviations used in this paper: cAMP, cyclic  AMP; 4-1BB-L, 4-1BB- 
ligand; ICAM-1, intercellular  adhesion molecule 1. 
CD8 T cells (8). It is a member of the nerve growth factor 
(NGF)/TNF receptor gene family, characterized by the pres- 
ence of cysteine-rich motifs in the extracellular domains (for 
reviews see references 10 and 11). 4-1BB mtLNA is induced 
in T  cells within hours of activation with anti-CD3  (12). 
However, surface expression of 4-1BB  is not detected until 
24-48 h after anti-CD3 treatment (8) and maximal expres- 
sion appears to require costimulation or cytokine treatment 
of the T  cells and takes  several days (12a).  Initially, it was 
reported that 4-1BB binds to extracellular matrix proteins 
(13). However, more recently a high affinity ligand for 4-1BB 
has been identified on activated macrophages (9) and mature 
B cells (14). 4-1BB-L shows homology to TNF, LT-ol, LT-B, 
CD40L,  and CD27L and thus appears  to be a member of 
an emerging family of molecules that bind to members of 
the NGF/TNF receptor family (11). 4-1BB-L in CV-1 cells 
has been shown to costimulate with Con A in activation of 
thymocytes and with PHA in costimulation of splenic T cells 
(9). Moreover, antibody-mediated cross-linking of 4-1BB on 
anti-CD3-activated T cells profoundly enhances T cell prolifer- 
ation (8). 
In this report we have analyzed the ability of a 4-1BB- 
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vation in the presence  and absence of B7 molecules.  These 
data provide further evidence for the importance of 4-1BB- 
L-4-1BB interaction in the costimulation of T  lymphocyte 
activation. 
Materials  and Methods 
Cell Lines, Antibodies and Reagents.  The APC lines used in this 
study are described in Table I. The BALB/c lymphomas M12 and 
K46J were originally described by Kim et al. (15). An Ia-negative 
variant of M12, M12.C3, transfected  with truncated A  k (M12.C3. 
5C2,16) and the autoreactive Ak-restricted T hybrid C8.A3 (16) 
were obtained from Dr. Laurie Glimcher (Harvard Medical  School, 
Boston, MA). K46J.73.35 (17), M12.C3.F6 (18), and M12.TDAK 
(19) transfectants have been described  previously. Cells were main- 
tained in RPMI-1640 containing 10% FCS (P.A. Biologicals,  Sydney, 
Australia), 50/~M 2-ME, MEM nonessential  amino acids (GIBCO 
BILL, Gaithersburg, MD), antibiotics, pyruvate, and glutamine as 
previously described (20). 
20C9 antibody, specific  for heat stable antigen (4) was provided 
as a culture supernatant by Dr. Yang Liu (New York University 
Medical Center, New York). The B7-1 specific  hybridoma 1610A1 
(21) was kindly provided by Dr. Hans Reiser (Dana Farber Cancer 
Institute, Boston, MA). The B7-2 specific hybridoma Gbl (22), 
the CD8-specific, rat IgG2a-secreting  hybridoma 53.72.6, the A  k- 
specific hybridoma 10-2.16, and the Ad-specific  hybridoma MKD6 
were obtained from the American Type Culture Collection (Rock- 
ville, MD). The ICAM-l-specific hybridoma YN1 (23) was kindly 
provided by Fumeo Takei (University of British Columbia, Van- 
couver, Canada) and the anti-CD3-secreting hybridoma 145-2Cll 
(24) was kindly provided by Dr. Jeff Bluestone (University of 
Chicago, Chicago, IL). Antibodies were purified using protein 
G-Sepharose and labeled with biotin according to Goding (25). 
The mAb 1AH2 is a subdone of the antibody 53A2 specific for 
4-1BB described previously (8). The 4-1BB-AP fusion protein was 
prepared as previously  described (14). The CTLA-4Ig fusion pro- 
tein (26) was provided in purified form by Peter Linsley (Bristol- 
Myers Squibb, Seattle, WA). Human placental AP was purchased 
from Sigma Chemical Co. (St. Louis, MO) and anti-AP was ob- 
tained from Medix Biotech Inc. (Foster City, CA). 
T Celllsolation.  6-8-wk-old  BALB/c female  mice  were obtained 
from Charles River Laboratory (St-Constant, Quebec, Canada). 
Spleen cell suspensions  were isolated  from 8-10-wk-old  mice, treated 
with 0.15 mM NH4C1 to lyse the RBC. MHC class II positive 
cells were depleted by treating the cell suspension with the A  d- 
specific antibody MKD6 plus low-tox baby rabbit complement 
(Cedarlane, Hornby, Ont., Canada). T cells were further purified 
by passage over T cell enrichment columns from R&D Systems 
Inc. (Minneapolis,  MN) and were ,v90% pure by anti-CD3 staining. 
Antigen Presentation Assays.  Either  10  s C8.A3 T hybrids or 
5 x  104 normal splenic T cells were mixed with 105 or 2  ￿  105 
B lymphoma cells, respectively,  and incubated overnight in the pres- 
ence of various blocking antibodies. Supernatants were harvested 
and assayed  for II:2 content using the CTLL indicator line as de- 
scribed (27). For both the I1:2 and the proliferation assays, data 
are expressed as mean  _+  SD of triplicate cultures. 
Primary MLR cultures were prepared from mouse spleen using 
2  x  10  s BALB/c responder and 8  x  105 C3H stimulator cells. 
Responder T cells were enriched  by passage through Sephadex G-10 
followed  by Ab plus complement treatment of the eluted cells using 
anti-CD8 and anti-class II (MKD6) antibody. The stimulator popu- 
lation was depleted of T cells using anti-Thy 1.2 (HO13.4), anti- 
CD4 (RL172), and anti-CD8 mAb plus complement. Anti-Thyl 
and anti-CD4  were provided by Michael Julius  (University of 
Toronto). The remaining viable cells were irradiated (2,000 fads). 
I1:2 content of the supernatants  was measured  on day  4 and prolifer- 
ation was measured on day 5, by harvesting cells that had been 
pulsed with [3H]thymidine for the previous 8 h of culture. 
Flow Cytometry.  For flow cytometric  analysis,  cells were washed 
once in PBS and 106 cells in 200/ll of PBS, 1% FCS, 2 mM NaN3 
were incubated with irrelevant antibody to block Fc receptors be- 
fore the  addition of biotinylated antibodies. After  incubation, 
samples were washed and incubated with 200 #1 of a 1-/~g/ml 
solution of PE-streptavidin (BioMeda, Foster City, CA), followed 
by further washing. Samples  were analyzed  on a FACScan  |  (Becton 
Dickinson & Co., Mountain View, CA). Samples were monitored 
for forward  versus side scatter and FL2 (for PE staining). Alignment 
was checked using Immunocheck beads and Autocomp software 
(Becton Dickinson & Co.). Propidium iodide staining and forward 
and side scatter were used to gate on live cells. Data were analyzed 
and plotted using Lysis  II software (Becton Dickinson & Co.). In 
some experiments, B lymphoma cells at a density of 5  x  10Vml 
were incubated overnight in complete medium containing 300 r 
dibutyryl-cyclic (cAMP), as previously described (27). 
Results 
CTLA-4-independent  Costimulation of T  Cells by K46J B 
Lymphomas.  Previous  work  from  our  laboratory  at  the 
University of Toronto and that of Laurie Glimcher has charac- 
terized the costimulatory requirements of a T  cell hybrid, 
C8.A3. This T hybrid fails to respond to M12 B lymphomas 
expressing truncated A k molecules (16) unless they have been 
stimulated with cAMP (27) to induce B7-1 and -2 expres- 
sion (28-30) or unless they have been transfected  with B7-1 
cDNA (28).  Here we show that in contrast to the results 
with M12 B lyrnphomas (16), the BALB/c B lymphoma, K46J, 
when transfected with genes encoding truncated A k mole- 
cules, does  not show the same antigen presentation defect 
(Table 1) and can stimulate C8.A3 T hybrids even in the pres- 
ence of CTLA-4Ig (Fig.  1).  The CTLA-4Ig was used at a 
concentration of 20 #g/ml, which is more than sufficient 
to give maximal inhibition of antigen presentation by M12 
cells (29 and data not shown). These data suggest that K46J 
lymphomas express a costimulatory activity that does  not 
involve CTLA-4 ligands. 
We also tested the ability of K46J cells to costimulate with 
immobilized anti-CD3 antibody to drive IL-2 production by 
normal T cells isolated from BALB/c spleens. We found that 
K46J lymphomas can costimulate normal T  cells and that 
this activity does not appear to be sensitive to inhibition with 
antibodies against ICAM-1 nor to antibodies to heat stable 
antigen added either alone or in combination with CTLA4Ig 
(data not shown). Thus the ability of K46J cells to deliver 
costimulatory  signals is independent of  B7 molecules, ICAM-1, 
and heat stable  antigen. 
K46J B Lymphomas Express an Anti-B7-2 (GL-1) Binding 
Molecule that Does Not Appear to  be Involved in  Costimula- 
tion.  Although the costimulatory activity of K46J B lym- 
phomas did not appear to be dependent on CTLA-4 ligands, 
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A k  A k  IL-2 produced by C8.A3 s 
molecule  specific 
APC  expressed*  fluorescence*  -  cAMP  + cAMP 
M12.C3.F6  wt/wt  203  320  nt 
M12.C3.5C2  -  10/- 12  43  <10  320 
M12.TDAK  -  10/- 12  181  <10  320 
K46J  none  0  <10  <10 
K46J.73.35  -  12/- 12  57  160  160 
*  -  10/- 12 or  -  12/- 12 indicates A k molecules altered by site-directed mutagenesis to encode proteins lacking 10 or 12 amino acids from the 
COOH terminus of the B chain and 12 amino acids from the COOH terminus of the o~ chain. M12.TDAK and K46J express wild-type A  d and 
E  a molecules as well as the transfected A  k molecules, whereas M12.C3.F6 and M12.C3.5C2 were obtained by transfecting the Ia negative cell line 
M12.C3  and express only wild-type or truncated A  k. 
* A  k surface expression was measured using FITC-10-2.16  antibody. Specific fluorescence refers to the signal obtained with FITC-10-2.16 minus 
that obtained with a negative control antibody. 
S C8.A3  are autoreactive, Ak-restricted T cell hybrids. IL-2 activity is expressed as the dilution of culture supernatant that  gives 50% maximum 
thymidine incorporation by CTLL cells. 
we analyzed the surface expression of these molecules on K46J 
B  lymphomas.  Surprisingly,  we found that although  K46J 
cells fail to bind CTLA-4Ig or anti-B7-1, they do stain with 
the B7-2-reactive antibody GL-1 but not with a control rat 
IgG2a antibody (data not  shown).  Despite the presence of 
a GL-1 (anti-B7-2) binding molecule on K46J ceils, B7-2 does 
not  appear to be responsible for the costimulatory activity 
of K46J B  lymphomas in that GL-1 antibody does not in- 
hibit antigen presentation  by K46J B  lymphomas (data not 
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Figure  1.  Antigen presentation by K46J B lymphomas is not blocked 
by CTLA-41g. 105 autoreactive, Ak-restricted C8.A3 T hybrids were cul- 
tured for 18 h with 105 K46J.73.75 or 105 M12.TDAK cells. Cell lines 
are described in Table 1. Untreated M12.TDAK are included as a negative 
control here, since they do not stimulate C8.A3 cells unless treated with 
cAMP to induce B7 molecules. Supernatants were harvested and assayed 
for the presence of IL-2 using CTLL cells. CTLA41g was added at a final 
concentration of 20 #g/ml. 
shown). Thus K46J cells express a molecule which binds B7- 
2-specific antibodies but does not  appear to be involved in 
costimulation  of T  cells.  Work is in progress to determine 
whether this molecule represents a mutated or posttransla- 
tionally modified form of B7-2 that lacks the CTLA-4 and 
CD28 binding site or whether it represents an unrelated mol- 
ecule  that  expresses  the  GL-1  epitope. 
Expression of 4-1BB-L on B Lymphomas.  As discussed above, 
4-1BB,  a member of the  TNF/NGF  receptor  family, is an 
activation  antigen  on  T  cells  that  has  been  implicated  in 
costimulation ofT lymphocyte growth. Its ligand, 4-1BB-L, 
shows sequence homology to TNF and is found on activated 
macrophages, B cells, and B lymphomas. We examined K46J 
B lymphomas for the expression of 4-1BB-L using a soluble 
form of 4-1BB  (14).  Fig.  2 A  shows  that  a  fusion protein 
consisting of the extracellular domain of 4-1BB linked to AP 
(4-1BB-AP) stains K46J B lymphomas, whereas the AP itself 
does not.  We therefore examined  the T  cell hybrid C8.A3 
for expression of 4-1BB using mAb  1AH2.  Resting C8.A3 
cells did not express detectable 4-1BB (data not shown), how- 
ever after overnight incubation with immobilized anti-CD3, 
4-1BB  surface expression  was  readily detected  (Fig.  2 B). 
It was of interest to determine whether 4-1BB ligand was 
also expressed  on  a B  lymphoma that  expressed B7  mole- 
cules.  Fig.  2 A  shows that M12 B  lymphomas express low 
levels of 4-1BB-L constitutively but  are induced  to express 
much higher  levels of 4-1BB-L upon  overnight  incubation 
in dibutyryl-cAMP, cAMP did not have an effect on 4-1BB-L 
expression on K46J cells,  which  already express high levels 
of the ligand  (data  not  shown). 
4-1BB-L Is Critically Involved in Costimulation by K46J B Lym- 
phomas.  Since activated C8.A3 cells express 4-1BB and K46J 
cells express its ligand, we tested the ability of the 4-1BB-AP 
fusion protein  to inhibit  IL-2 production  by C8.A3  in re- 
sponse to K46J.73.75  cells. Fig. 3 A  shows that the 4-1BB- 
AP fusion protein blocks IL-2 production by C8.A3 cells re- 
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Figure  2.  Expression  of the 4-1BB-L and 4-1BB counter-receptors  on (A) B cells and (B) T  cells, respectively. (.4) K46J B lymphoma cells were 
stained with either AP (open histograms) or 41BB-AP (filled histograms) followed by biotinylated  anti-AP antibody.  PE-streptavidin  was used as the third 
step in the detection  protocol.  M12TDAK cells were untreated  or treated with dibutyryl-cAMP  as indicated on the figure and stained with 4-1BB-AP 
(untreated, cAMP) or AP alone (unlabeled histogram). (B) Filled histograms  represent C8.A3 cells incubated  overnight  on plates coated with 10/~g/ml 
anti-CD3 antibody  before flow cytometry analysis for 4-1BB expression,  using  biotinylated  1AH2 antibody.  Open histograms  represent  staining of 
C8.A3 T  cells with control biotinylated  antibody.  PE-streptavidin  was used as the second step to detect  biotinylated  antibodies. 
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Figure  3.  4-1BB-AP blocks Ib2 production by C8.A3 T hybrids and 
by normal murine T cells. (A) C8.A3 T hybrids were incubated with A k 
transfected K46J B lymphomas (K46J. 73.35) and IL-2 production was as- 
sayed at 18 h using CTLL cells. (B) Normal murine T cells were co-cultured 
sponding  to  Ak-transfected  K46J  B  lymphomas  to  near 
background levels whereas CTLA-4Ig has little or no effect. 
Fig. 3 B  shows that  IL-2 production by normal  T  cells to 
K46J plus anti-CD3  is also profoundly blocked by 4-1BB- 
AP fusion protein. In this and other experiments with normal 
T  cells we observed some inhibition  with  CTLA4Ig  also. 
Inasmuch as K46J does not express CTLA-4 ligands, this is 
likely due to failure to remove all the APC during T cell iso- 
lation. 
Although AP itself did not block T cell activation by K46J 
cells,  it is formally possible that  the 4-1BB fusion protein 
was somehow inhibitory to the T cells by some means other 
than by blocking the interaction  of 4-1BB with its ligand. 
To test this possibility, we looked at the response of C8.A3 
T  hybrids  to immobilized  anti-CD3.  Although  C8.A3  T 
hybrids require costimulation when responding to Ag/MHC 
II, they do respond to anti-CD3 alone, as in the case for most 
T  cell hybrids. Fig. 4 shows that 4-1BB-AP does not affect 
IL-2 production by C8.A3 T  cells responding to anti-CD3 
immobilized  on plastic. 
To examine whether 4-1BB plays a role in T  cell activa- 
tion in the presence of B7 molecules, we tested the effect of 
4-1BB-AP on T cell activation by M12 B lymphomas treated 
with cAMP. After overnight treatment with cAMP, M12 B 
lymphomas express limited amounts of B7-1 and high levels 
of B7-2 (data not shown). Fig. 5 shows that 4-IBB-AP pro- 
foundly blocks the  activation  of C8.A3  T  cells  by Ak-ex - 
pressing M12 cells. Anti-B7-1 shows little or no effect in this 
experiment,  presumably because high level B7-1 expression 
requires longer than  the overnight  APC activation carried 
with K46J B cells and immobilized anti-CD3 and assayed for Ib2 produc- 
tion as described in Fig. 2. The 4-1BB-AP fusion protein and the AP were 
added at a final concentration  of 10 #g/ml. CTLA4Ig was added at a final 
concentration  of 20 ~g/ml. 
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Figure  4.  Soluble 4-1BB does not inhibit anti-CD3 activated C8.A3 
T hybrids.  10  s C8.A3 T cells were incubated overnight on plates coated 
with 10 ~tg/ml anti-CD3. Ib2 production was assayed using CTLL cells. 
The 41BB-AP fusion protein and the AP were added  at the beginning 
of the incubation at a final concentration of 10 #g/ml. 
out here (28). Anti-B7-2 gave inhibition comparable to that 
observed with 4-1BB-AP alone. In combination, anti-B7-1, 
anti-B7-2, and 4-1BB-AP completely inhibited IL-2 produc- 
tion by C8.A3 in response to cAMP-treated M12 cells. Thus 
B7 molecules and 4-1BB-L each contribute independently to 
T  cell activation when expressed on the same APC. 
Role  of 4-1BB in Antigen  Presentation by Splenic APC. 
4-1BB-L has been identified on activated macrophages as well 
as on B cells. To determine whether 4-1BB-L plays a role 
in T  cell activation by splenic APC as well as by K46J B 
lymphomas we tested the ability of 4-1BB-AP to block T 
cell responses in a BALB/c anti-C3H MLR. Fig. 6 shows 
that both 4-1BB-AP and CTLA-4Ig added individually pro- 
foundly block proliferation  and IL-2 production by the al- 
loreactive T  cells. The combination of the two completely 
abrogated the response. These data suggest that both 4-1BB-L 
and B7 molecules play a role in costimulation by splenic APC. 
Discussion 
In this report we have shown that a fusion protein between 
4-1BB and AP profoundly blocks T cell activation both by 
B lymphomas and by unfractionated spleen cells. The effect 
of the 4-1BB-AP fusion protein appears to be on APC-T cell 
interaction,  since 4-1BB-AP does not block T cell activation 
by immobilized anti-CD3. These data suggest that the fu- 
sion protein is blocking antigen presentation  by blocking 
the interaction between 4-1BB and its ligand on the APC. 
4-1BB-L, a member of the TNF gene family, recently has 
been identified as a high affinity ligand for 4-1BB on acti- 
vated B cells and macrophages (9). However, the present ex- 
periments do not rule out that alternate low affinity ligands 
for 4-1.BB, namely extraceUular  matrix components, also play 
a role (13). 
We find that 4-1BB plays a role in costimulation of T cell 
activation both in the presence of B7 molecules and in their 
apparent absence. M12 ceils, when treated overnight with 
dibutyryl-cAMP, express both B7-2 and 4-1BB-L as well as 
low levels of B7-1. Under these conditions of antigen pre- 
sentation we find that CTLA-4Ig and 4-1BB-AP each inhibit 
substantially. In contrast to the effects of CTLA4Ig alone 
(29) the combination of anti-B7-1,  anti-B7-2,  and 4-1BB- 
AP completely  blocks antigen presentation by cAMP-treated 
M12 cells, suggesting  that these molecules account for the 
majority of the costimulatory ligands on cAMP-treated M12 
cells. When spleen cells are used as stimulators in an MLR, 
we find that CTLA-4Ig and 4-1BB-AP each inhibit almost 
completely on their own. This suggests that high level IL-2 
production may require multiple costimulatory signals, per- 
haps acting sequentially.  Removal of  either one of these signals 
is sufficient to abrogate  the major part of the response. 
On K46J B lymphomas which lack functional B7 mole- 
cules, 4-1BB-L appears to be capable of costimulating C8.A3 
T cells in the absence of B7 molecules. Thus 4-1BB-4-1BB 
ligand interaction in the absence of B7, can costimulate IL-2 
production. However, we do not know whether other mol- 
ecules on K46J are required  or whether 4-1BB-L alone is 
sufficient for costimulation.  This question will require anal- 
ysis of the function of 4-1BB-L in the absence of other APC 
molecules. Goodwin et al. (9) showed costimulation of splenic 
T cells with PHA plus 4-1BB-L transfected CV-1 cells. How- 
ever, the fact that they used a lectin in these studies may have 
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Figure  5.  4-1BB-AP and anti-B7 antibodies have additive 
effects on the ability of M12 B cells to costimulate T cells. 
C8.A3 T cells were incubated with M12.TDAK B lymphomas 
and IL-2 production was assayed using CTLL cells as described 
in Materials and Methods. Anti-B7-1 (1610A1) and anti-B7-2 
(GL-1) antibodies were added to cultures at a final concentra- 
tion of 20/xg/ml. The 4-1BB-AP fusion protein and the AP 
were added  at a final concentration of 10/~g/ml. 
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Figure  6.  4-1BB-AP blocks proliferation and Ib2 produc- 
tion in a 5-d BALB/c anti-C3H MLR.. (.4) Proliferation  of 
T cells,  measured at 5 d. (B) IL-2 content of the supernatant 
at  4  d  was  measured  using  CTLL  cells.  CTLA-41g  and 
4-1BB-AP were each  added at  10/~g/ml.  Control refers to 
the addition of 10/~g/ml human IgG1. In other experiments, 
AP was used as a control with a similar  lack  of effect. 
resulted in cross-linking of several T cell surface proteins. On 
the other hand, Pollok et al. (8) have shown that the 53A2 
mAb, specific for 4-1BB, can costimulate with anti-CD3 to 
activate splenic T cells, again suggesting that 4-1BB-4-1BB-L 
interaction can function independently  of B7 molecules to 
costimulate  lymphocyte growth. 
The C8.A3 T hybrids used here, although costimulatory 
molecule dependent  when stimulated  using Ag/MHC,  are 
costimulatory molecule independent when stimulated with 
anti-CD3. Therefore, it was of interest to determine whether 
4-1BB-L-4-1BB  interaction plays a role in normal T ceil acti- 
vation.  We found that K46J B lymphomas can costimulate 
with anti-CD3 to activate normal splenic T cells to produce 
IL-2 and induce T cell proliferation. This costimulatory  ac- 
tivity of K46J was blocked by 4-1BB-AP, suggesting the im- 
portance of 4-1BB-4-1BB-L interaction in normal T cell ac- 
tivation.  It is di~cult however to conclude from these data 
that 4-1BB-L  alone is costimulatory because we often ob- 
served a small amount of inhibition with CTLA-4Ig in these 
experiments. This inhibition with CTLA-4Ig is presumably 
990  Costimulatory Function  of 4-1BB  Ligand due to residual APC in the T  cell preparations,  since K46J 
cells  do not  stain with  CTLA-4Ig. 
It is perhaps surprising that 4-1BB-AP blocks T cell acti- 
vation by M12 B lymphomas which also express B7 mole- 
cules,  because B7-transfected CHO cells  have been shown 
to be suffident to provide costimulation for T cells (30-33). 
In those studies the levels of B7 used were higher than those 
found on activated B cells and furthermore, the T cells were 
stimulated with anti-CD3. It is likely that under normal con- 
ditions when the physiological ligand for TCR (Ag/MHC) 
is used that several costimulatory molecules will contribute 
to T  cell activation. 
On C8.A3 T cells, 4-1BB is detectable on the cell surface 
after overnight incubation with anti-CD3 (Fig. 2 B), consis- 
tent with our observation that 4-1BB-4-1BB-L plays a role 
in antigen  presentation  within  the first 24 h  of activation 
of C8.A3 T  cells. However, for normal splenic T cells max- 
imal surface expression of 4-1BB requires costimulation or 
exposure to cytokines and takes several days (12a). Therefore, 
one must ask how 4-1BB-AP can block T cell activation be- 
fore the surface expression of 4-1BB is detectable. Previous 
work (12) has established that 4-1BB mRNA is detectable 
within a few hours of stimulation with anti-CD3.  It is pos- 
sible that low levels of 4-1BB are present on the cell surface 
within hours of contact of the T  cells with APC and that 
these levels are sufficient to initiate T  cell activation. These 
initial signals would then result in further amplification of 
4-1BB expression on the T  cell.  Alternatively,  other mole- 
cules on K46J cells may contribute to the costimulatory signals 
which then  allow induction  of more 4-1BB on the T  cell 
and further  amplification  of the costimulatory  signals. 
Cross-linking of a number of surface receptors on T cells 
has been shown to augment T cell activation. However, many 
of these interactions function to enhance signals  induced via 
the TCR, i.e., "signal 1". What distinguishes the CD28-B7 
interaction  is that  CD28 engagement results in the induc- 
tion of a distinct signal transduction pathway, hence the widely 
accepted view that CD28 is a major recipient of "signal 2" 
(2, 3). 4-1BB has been shown to associate with p56  lck (34), 
but at this time little else is known about its signal trans- 
ducing  properties.  It  remains  to  be  seen  whether  signals 
emanating  from  4-1BB intersect  those  signal  transducing 
pathways activated by TCR, and/or  CD28. 
4-1BB-L and 4-1BB are members of an emerging family 
of cytokine-like, cytokine receptor-like molecules, including 
TNF, TNFR;  CD40L,  CD40;  and CD70,  CD27 (9, 35). 
It is of interest, that CD27 on T cells interacting with CD70 
on human B cells shares many of the features of the 4-1BB- 
4-1BB-L system (36, 37). CD27 is present at low levels on 
mature T cells and upregulated by TCR signaling.  Its ligand, 
CD70 is absent on resting B cells but upregulated by CD40 
signaling.  CD70 has  also been shown to be costimulatory 
for T cells and to have additive effects with B7, however CD70 
has  more of an effect on TNF-c~ production  than on IL-2 
and IL-4 production by human T  cells (36).  It is tempting 
to  speculate  that  various  combinations  of B7,  4-1BB-L, 
CD27L, and perhaps other costimulatory molecules, might 
influence the phenotype of T  cell response one obtains. 
We have shown that in M12 cells, both B7 molecules and 
4-1BB-L are upregnlated by cAMP treatment.  Thus several 
costimulatory molecules on APC can be induced by activa- 
tion. During antigen presentation, it is likely that both 4-1BB 
and  4-1BB-L  are  upregulated  reciprocally  allowing  an 
amplification of the initial signals  in much the same way as 
B7 and CD28 molecules and CD27 and CD70 are upregu- 
lated during T  cell activation.  This back and forth interac- 
tion between the two cells might  serve to reinforce initial 
signaling events that take place upon the engagement of  just 
a few TCR and a few costimulatory receptors by their ligands, 
rendering  the T cell exquisitely sensitive to antigenic challenge. 
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